Short Interest in Generation Bio Co. (NASDAQ:GBIO) Declines By 11.8%

Generation Bio Co. (NASDAQ:GBIO - Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,270,000 shares, a decline of 11.8% from the February 29th total of 1,440,000 shares. Based on an average daily trading volume, of 327,000 shares, the short-interest ratio is presently 3.9 days. Currently, 2.6% of the shares of the stock are short sold.

Generation Bio Stock Up 10.0 %

GBIO traded up $0.37 during trading on Friday, reaching $4.07. 442,530 shares of the stock traded hands, compared to its average volume of 279,076. The stock has a market capitalization of $270.57 million, a PE ratio of -2.08 and a beta of 2.70. The stock's 50-day moving average is $2.50 and its 200 day moving average is $2.20. Generation Bio has a 12 month low of $0.86 and a 12 month high of $6.98.

Generation Bio (NASDAQ:GBIO - Get Free Report) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.12). The firm had revenue of $2.88 million for the quarter, compared to the consensus estimate of $3.05 million. As a group, equities research analysts anticipate that Generation Bio will post -1.41 EPS for the current year.

Analyst Ratings Changes

GBIO has been the subject of several research analyst reports. Needham & Company LLC lowered their price target on shares of Generation Bio from $14.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, March 7th. Wedbush restated an "outperform" rating and issued a $5.00 price objective on shares of Generation Bio in a report on Thursday, March 7th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Generation Bio presently has a consensus rating of "Hold" and an average target price of $8.00.

Hedge Funds Weigh In On Generation Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in shares of Generation Bio by 0.6% in the 1st quarter. JPMorgan Chase & Co. now owns 463,854 shares of the company's stock worth $1,994,000 after acquiring an additional 2,714 shares during the last quarter. Alliancebernstein L.P. increased its stake in Generation Bio by 5.8% in the 3rd quarter. Alliancebernstein L.P. now owns 53,006 shares of the company's stock valued at $281,000 after buying an additional 2,900 shares during the last quarter. Renaissance Technologies LLC increased its stake in Generation Bio by 1.1% in the 3rd quarter. Renaissance Technologies LLC now owns 290,200 shares of the company's stock valued at $1,541,000 after buying an additional 3,071 shares during the last quarter. State Street Corp increased its stake in shares of Generation Bio by 0.4% during the 3rd quarter. State Street Corp now owns 918,491 shares of the company's stock worth $4,877,000 after purchasing an additional 3,563 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of Generation Bio by 63.1% during the 2nd quarter. UBS Group AG now owns 10,077 shares of the company's stock worth $66,000 after purchasing an additional 3,900 shares during the last quarter. Institutional investors own 95.22% of the company's stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.